OBJECTIVETo compare the effect of acupoint injection desensitization with autoblood and routine combined therapy for treatment of chronic urticaria.METHODSTwo hundred patients with chronic urticaria were randomly divided into an acupoint injection with autoblood (AJA) group and a medicine group, 100 cases in each group. The AJA group was treated by acupoint injection desensitization with autoblood and Dazhui (GV 14), Fengfu (GV 16), Feishu (BL 13), Neiguan (PC 6) and etc. were selected, 3-5 acupoints each time, once every three days, 30 days for a course. The therapeutic effect was assessed after one course. The medicine group was treated with external application of Dexamethasone Acetate cream, twice a day, and oral administration of Setastine Hydrochloride, twice a day, 1 mg each time and the treatment duration was the same as that in the AJA group.RESULTSThe clinical cured rate was 66.0% (66/100) in the AJA group, which was superior to that of 0 (0/100) in the medicine group (P < 0.05).CONCLUSIONThe acupoint injection desensitization with autoblood has obvious therapeutic effect on chronic urticaria with no apparent dependence and rebound problem.

01 Jan 1994·Therapia Hungarica (English edition)

Assessing the sedative (adverse) effects of antiallergic drugs by quantitative electroencephalography: effects of setastine a non-sedating antihistaminic drug.

Article

Author: Veres, J ; Rajna, P

In order to assess the effects of Loderix (setastine) on the EEG ten healthy male volunteers were investigated in double-blind, placebo-controlled, cross-over arrangement. In addition to the test compound (Loderix) volunteers were treated with vehicle and with two referent drugs (terfenadine, Teldane, and chloropyramine HCl, Suprastin) possessing sedative effects of very different degrees. The different effects of the referent drugs on the central nervous system (CNS) were precisely indicated by the posterior alpha/theta ratio in the EEG. This marker parameter was affected by Loderix in the same direction as by Teldane and in the opposite direction as compared to Suprastin. In addition, Loderix increased the beta frequency range in the median areas of both hemispheres, moreover, it increased the total EEG power. The latter changes raise the question if Loderix has an "own" action on the EEG. (The observed "own" effect could not even be brought into connection with decrease of the vigilance level). The results strengthen the view that the action of Loderix on the EEG is similar to that of induced by Teldane, a drug very favourable in respect of the sedative side effects. Moreover, the drug did not affect the EEG power spectra in a direction that referred to sedative action. The spectral parameters in the "pharmaco" EEG recordings seem to be useful in the objective definition of the central (psychotropic) side-effects of drugs. This is a methodical achievement of the present study.

01 Jan 1993·Therapia Hungarica (English edition)

Comparative clinical examination of Loderix (setastinum) and astemizole in pollenosis.

Article

Author: Szilágyi, R ; Karácsonyi, E ; Mülbacher, S ; Gacsályi, I ; Radics, K ; Herjavecz, I

The action and side-effects of Loderix (EGIS) were examined in comparison with Hismanal (Janssen) containing the non-sedative H1-receptor antagonist astemizole, by double-blind, cross-over, self-controlled method. On the basis of the changes observed in response to the two drugs in the symptoms of rhinoconjunctivitis and asthma of 21 patients suffering from pollenosis Loderix proved to be of the same value as Hismanal considering both clinical effectivity and side-effects.

100 Deals associated with Setastine Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
-	Setastine Hydrochloride	R06A D11AH	-

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Rhinitis, Allergic, Perennial	CN	Huiyinbi Group Fuzhou Pharmaceutical Co Ltd	23 May 2005
Urticaria	CN	Huiyinbi Group Fuzhou Pharmaceutical Co Ltd	23 May 2005
Hypersensitivity	HU	Egis SA	01 Jan 1987

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis